Cargando…
Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo.
The growth rate of the MAC16 tumour in cachectic animals was significantly enhanced by the hypolipidemic agent bezafibrate, while the growth rate of a histologically similar tumour, the MAC13, which grows without an effect on host body compartments was unaffected. Growth of the MAC16 in vitro was un...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977866/ https://www.ncbi.nlm.nih.gov/pubmed/1764364 |
_version_ | 1782135353698680832 |
---|---|
author | Mulligan, H. D. Tisdale, M. J. |
author_facet | Mulligan, H. D. Tisdale, M. J. |
author_sort | Mulligan, H. D. |
collection | PubMed |
description | The growth rate of the MAC16 tumour in cachectic animals was significantly enhanced by the hypolipidemic agent bezafibrate, while the growth rate of a histologically similar tumour, the MAC13, which grows without an effect on host body compartments was unaffected. Growth of the MAC16 in vitro was unaffected by bezafibrate, suggesting that it was an in vivo phenomenon only. The stimulatory effect of bezafibrate correlated with the maximum plasma levels of free fatty acids (FFA) arising from the catabolism of adipose tissue. Accumulation of 14C-lipid from 1-14C-triolein administered by intragastric intubation was enhanced in heart, gastrocnemius muscle and tumour of bezafibrate treated animals, while the total lipid absorption did not differ from solvent treated controls. The increased lipid accumulation in the heart, but not the tumour correlated with an increased tissue lipoprotein lipase level. The increased tumour level may arise from an increased uptake of FFA arising from a weakening of the bonds between FFA and albumin. These results suggest that growth of certain tumours is dependent on maintaining sufficient lipid levels and that the lipid mobilising effect of the tumour may be necessary to sustain tumour growth. |
format | Text |
id | pubmed-1977866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1991 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19778662009-09-10 Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo. Mulligan, H. D. Tisdale, M. J. Br J Cancer Research Article The growth rate of the MAC16 tumour in cachectic animals was significantly enhanced by the hypolipidemic agent bezafibrate, while the growth rate of a histologically similar tumour, the MAC13, which grows without an effect on host body compartments was unaffected. Growth of the MAC16 in vitro was unaffected by bezafibrate, suggesting that it was an in vivo phenomenon only. The stimulatory effect of bezafibrate correlated with the maximum plasma levels of free fatty acids (FFA) arising from the catabolism of adipose tissue. Accumulation of 14C-lipid from 1-14C-triolein administered by intragastric intubation was enhanced in heart, gastrocnemius muscle and tumour of bezafibrate treated animals, while the total lipid absorption did not differ from solvent treated controls. The increased lipid accumulation in the heart, but not the tumour correlated with an increased tissue lipoprotein lipase level. The increased tumour level may arise from an increased uptake of FFA arising from a weakening of the bonds between FFA and albumin. These results suggest that growth of certain tumours is dependent on maintaining sufficient lipid levels and that the lipid mobilising effect of the tumour may be necessary to sustain tumour growth. Nature Publishing Group 1991-12 /pmc/articles/PMC1977866/ /pubmed/1764364 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Mulligan, H. D. Tisdale, M. J. Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo. |
title | Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo. |
title_full | Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo. |
title_fullStr | Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo. |
title_full_unstemmed | Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo. |
title_short | Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo. |
title_sort | effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977866/ https://www.ncbi.nlm.nih.gov/pubmed/1764364 |
work_keys_str_mv | AT mulliganhd effectofthelipidloweringagentbezafibrateontumourgrowthrateinvivo AT tisdalemj effectofthelipidloweringagentbezafibrateontumourgrowthrateinvivo |